• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

在中低收入国家获得药物和开展临床试验。

Access to medications and conducting clinical trials in LMICs.

机构信息

Division of Nephrology and Hypertension, Department of Medicine, Groote Schuur Hospital and University of Cape Town, Observatory 7925, Cape Town, South Africa.

Wits Reproductive Health and HIV Institute, University of the Witwatersrand, PO Box 2616, Saxonwold 2132, South Africa.

出版信息

Nat Rev Nephrol. 2015 Mar;11(3):189-94. doi: 10.1038/nrneph.2015.6. Epub 2015 Feb 10.

DOI:10.1038/nrneph.2015.6
PMID:25668002
Abstract

Access to essential medications is limited in many low-to-middle income countries (LMICs) and those that are available may be prohibitively expensive to the general population. Clinical trials have been suggested as an approach to improve drug access in LMICs but the number of trials conducted in these countries is small because of regulatory issues and a lack of infrastructure. In this article, Nature Reviews Nephrology asks three experts their opinions on how to improve drug access and increase the numbers of clinical trials conducted in LMICs.

摘要

在许多中低收入国家(LMICs),基本药物的可及性受到限制,而那些可用的药物对于普通民众来说可能过于昂贵。有人建议开展临床试验,以改善 LMICs 的药物可及性,但由于监管问题和基础设施缺乏,在这些国家开展的临床试验数量很少。在这篇文章中,《自然评论:肾病学》采访了三位专家,询问他们对如何改善药物可及性以及增加在 LMICs 开展临床试验数量的看法。

相似文献

1
Access to medications and conducting clinical trials in LMICs.在中低收入国家获得药物和开展临床试验。
Nat Rev Nephrol. 2015 Mar;11(3):189-94. doi: 10.1038/nrneph.2015.6. Epub 2015 Feb 10.
2
Improved drug access in low and middle-income countries.改善低收入和中等收入国家的药物可及性。
Lancet Oncol. 2016 May;17(5):539. doi: 10.1016/S1470-2045(16)30068-7. Epub 2016 Apr 27.
3
Formulary expansion to provide access to medications prescribed by a specialist in a low-income population.
J Health Care Poor Underserved. 2012 May;23(2):834-41. doi: 10.1353/hpu.2012.0053.
4
Poverty and access to health care in developing countries.发展中国家的贫困与医疗保健服务可及性
Ann N Y Acad Sci. 2008;1136:161-71. doi: 10.1196/annals.1425.011. Epub 2007 Oct 22.
5
Glossary of access to health care and related concepts for low- and middle-income countries (LMICs): a critical review of international literature.中低收入国家(LMICs)获取医疗保健和相关概念词汇表:国际文献的批判性回顾。
Int J Health Serv. 2014;44(4):845-61. doi: 10.2190/HS.44.4.j.
6
International assistance and cooperation for access to essential medicines.获取基本药物的国际援助与合作。
Health Hum Rights. 2010 Jun 15;12(1):73-81.
7
Stakeholder Views of Clinical Trials in Low- and Middle-Income Countries: A Systematic Review.低收入和中等收入国家临床试验的利益相关者观点:一项系统综述
Pediatrics. 2016 Feb;137(2):e20152800. doi: 10.1542/peds.2015-2800. Epub 2016 Jan 26.
8
Essential medicines for COPD and asthma in low and middle-income countries.中低收入国家的 COPD 和哮喘基本药物。
Thorax. 2014 Dec;69(12):1149-51. doi: 10.1136/thoraxjnl-2014-205249. Epub 2014 Mar 3.
9
Radiation therapy infrastructure and human resources in low- and middle-income countries: present status and projections for 2020.中低收入国家的放射治疗基础设施和人力资源:现状和 2020 年预测。
Int J Radiat Oncol Biol Phys. 2014 Jul 1;89(3):448-57. doi: 10.1016/j.ijrobp.2014.03.002. Epub 2014 Apr 18.
10
Cardiac rehabilitation services in low- and middle-income countries: a scoping review.低收入和中等收入国家的心脏康复服务:一项范围综述。
J Cardiovasc Nurs. 2014 Sep-Oct;29(5):454-63. doi: 10.1097/JCN.0b013e31829c1414.

引用本文的文献

1
Vaccine Research Trends in Africa from 2016 to Mid-2024: A Bibliometric Analysis.2016年至2024年年中非洲的疫苗研究趋势:文献计量分析
Vaccines (Basel). 2025 May 12;13(5):509. doi: 10.3390/vaccines13050509.
2
Disparities in COVID-19 clinical studies from high-income and low-and middle-income countries.高收入和中低收入国家 COVID-19 临床研究中的差异。
Int J Infect Dis. 2023 Jul;132:9-16. doi: 10.1016/j.ijid.2023.04.393. Epub 2023 Apr 15.
3
International Society of Nephrology Global Kidney Health Atlas: structures, organization, and services for the management of kidney failure in Africa.

本文引用的文献

1
Training nephrologists from developing countries: does it have a positive impact?培养发展中国家的肾病学家:这有积极影响吗?
Kidney Int Suppl (2011). 2012 Aug;2(3):275-278. doi: 10.1038/kisup.2012.32.
2
"To patent or not to patent? the case of Novartis' cancer drug Glivec in India".是否申请专利?诺华抗癌药物格列卫在印度的案例。
Global Health. 2014 Jan 6;10:3. doi: 10.1186/1744-8603-10-3.
3
Chronic kidney disease: global dimension and perspectives.慢性肾脏病:全球维度与展望。
国际肾脏病学会全球肾脏健康地图集:非洲肾衰竭管理的结构、组织和服务
Kidney Int Suppl (2011). 2021 May;11(2):e11-e23. doi: 10.1016/j.kisu.2021.01.009. Epub 2021 Apr 12.
4
Engaging Patients for Clinical Trials in Africa: Patient-Centered Approaches.在非洲让患者参与临床试验:以患者为中心的方法。
JCO Glob Oncol. 2020 Jun;6:942-947. doi: 10.1200/JGO.19.00190.
5
The Myeloproliferative Neoplasm Landscape: A Patient's Eye View.骨髓增殖性肿瘤全景:患者视角。
Adv Ther. 2020 May;37(5):2050-2070. doi: 10.1007/s12325-020-01314-0. Epub 2020 Apr 23.
6
Challenges for sustainable end-stage kidney disease care in low-middle-income countries: the problem of the workforce.低收入和中等收入国家可持续的终末期肾病护理面临的挑战:劳动力问题。
Kidney Int Suppl (2011). 2020 Mar;10(1):e49-e54. doi: 10.1016/j.kisu.2019.11.007. Epub 2020 Feb 19.
7
Description of vaccine clinical trials in Africa: a narrative review.非洲疫苗临床试验描述:叙事性综述。
Hum Vaccin Immunother. 2020 Apr 2;16(4):972-980. doi: 10.1080/21645515.2019.1693720. Epub 2019 Dec 12.
8
Nephrology in South Africa: Not Yet .南非的肾脏病学:尚未成熟。
Kidney Dis (Basel). 2019 Jun;5(3):189-196. doi: 10.1159/000497324. Epub 2019 Mar 22.
9
Human dignity as a basis for providing post-trial access to healthcare for research participants: a South African perspective.将人类尊严作为为研究参与者提供审判后医疗保健服务的基础:南非视角。
Med Health Care Philos. 2018 Mar;21(1):139-155. doi: 10.1007/s11019-017-9782-1.
10
Health and Ethical Consequences of Outsourcing Pivotal Clinical Trials to Latin America: A Cross-Sectional, Descriptive Study.将关键临床试验外包至拉丁美洲的健康与伦理后果:一项横断面描述性研究
PLoS One. 2016 Jun 23;11(6):e0157756. doi: 10.1371/journal.pone.0157756. eCollection 2016.
Lancet. 2013 Jul 20;382(9888):260-72. doi: 10.1016/S0140-6736(13)60687-X. Epub 2013 May 31.
4
Six pairs of things to celebrate on International Clinical Trials Day.国际临床试验日值得庆祝的六件事。
Trials. 2013 May 20;14:128. doi: 10.1186/1745-6215-14-128.
5
How academia and the pharmaceutical industry can work together: the president's lecture, annual meeting of the American Thoracic Society, San Francisco, California.学术界和制药行业如何携手合作:主席演讲,美国胸科学会年会,加利福尼亚州旧金山。
Ann Am Thorac Soc. 2013 Feb;10(1):31-8. doi: 10.1513/AnnalsATS.201209-075PS.
6
India tightens regulation of clinical trials to safeguard participants.印度加强对临床试验的监管以保护参与者。
BMJ. 2013 Feb 25;346:f1275. doi: 10.1136/bmj.f1275.
7
Impact of regulatory requirements on medicine registration in African countries - perceptions and experiences of pharmaceutical companies in South Africa.监管要求对非洲国家药品注册的影响——南非制药公司的看法与经验
South Med Rev. 2012 Jul;5(1):31-7. Epub 2012 Jul 23.
8
Quality of online pharmacies and websites selling prescription drugs: a systematic review.在线药店及销售处方药网站的质量:一项系统评价
J Med Internet Res. 2011 Sep 30;13(3):e74. doi: 10.2196/jmir.1795.
9
The African medicines regulatory harmonization initiative: rationale and benefits.非洲药品监管协调倡议:原理与效益。
Clin Pharmacol Ther. 2011 Feb;89(2):176-8. doi: 10.1038/clpt.2010.299.
10
Tackling the booming trade in counterfeit drugs.应对假药贸易的蓬勃发展。
Lancet. 2010 Nov 20;376(9754):1725-6. doi: 10.1016/s0140-6736(10)62118-6.